Massachusetts General Hospital

Accepting patients

MonumenTAL-3

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

CFT7455

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more
  • Phase 1/2

Not yet accepting

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Not yet accepting

KarMMa-9

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Learn more
  • CAR T Cell
  • Immunomodulatory Drug
  • BCMA
  • Randomization
  • Phase 3

Accepting patients

Daratumumab Combination Therapy

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Learn more
  • Monoclonal Antibody
  • Proteasome Inhibitor
  • CD38
  • Phase 2

Not currently accepting

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2

Accepting patients

iMMAGINE-1

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

Elranatamab as Consolidation

A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 2

Not yet accepting

Marizomib for Myeloma Patients with CNS

Marizomib Central Nervous System (CNS)
Learn more
  • Proteasome Inhibitor
  • Phase 2

Accepting patients

BCMA CAR-T

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 1
  • Has results
7 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

BCMA Therapy

Advanced Filters

Trial Enrollment Status

Classifications

Targets

Trial Type

Phase